Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · Real-Time Price · USD
0.7859
+0.0131 (1.70%)
At close: Aug 13, 2025, 4:00 PM
0.7722
-0.0137 (-1.74%)
Pre-market: Aug 14, 2025, 8:47 AM EDT
Atossa Therapeutics Employees
Atossa Therapeutics had 15 employees as of December 31, 2024. The number of employees increased by 3 or 25.00% compared to the previous year.
Employees
15
Change (1Y)
3
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,914,533
Market Cap
101.52M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ATOS News
- 2 days ago - Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update - PRNewsWire
- 16 days ago - Atossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer - PRNewsWire
- 2 months ago - Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference - PRNewsWire
- 3 months ago - Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22 - Accesswire
- 3 months ago - Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen - PRNewsWire
- 3 months ago - Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update - PRNewsWire
- 3 months ago - Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio - GlobeNewsWire
- 3 months ago - Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025 - GlobeNewsWire